« Return to News | Awards & Advancement

Saladax Biomedical names Harter president and CEO

Monday, June 18, 2012 11:35 AM

Saladax Biomedical, a Bethlehem, Penn.-based privately held company developing and commercializing novel diagnostic, has appointed Kevin M. Harter as president and chief executive officer.

Harter, a co-founder and senior vice president of the Life Science Greenhouse, a public-private life sciences investment partnership, has been serving as interim CEO of Saladax since January 2012. From 2007 to 2011, Harter served as executive chairman of Saladax, a LSG-portfolio company, where he led multiple, successful funding rounds and strategic deals for the company.

He also co-founded Keystone Medical Systems in 1990 and managed the company through significant growth until its acquisition by publicly-held Continental Medical Systems. Prior to Keystone, Harter held several positions within the Pennsylvania Blue Shield organization, including vice president, technology, and has contributed significantly to the development of the field of electronic claims, electronic medical records and physician practice management.  He has held more than two dozen board seats in healthcare, technology and financial companies. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.